Boston Scientific agrees takeover of Apama Medical

Boston Scientific has announced the acquisition of Apama Medical, a medical technology company developing technology for the treatment of atrial fibrillation.

The deal will see Boston Scientific pay an initial upfront cash fee of $175 million (131.9 million pounds), plus up to $125 million in additional contingent payments based on the achievement of clinical and regulatory milestones between 2018 and 2020.

Apama Medical is currently developing the new Apama radiofrequency balloon catheter system for the treatment of atrial fibrillation, with the system designed to combine the benefits of radiofrequency point-by-point and balloon-based ablation approaches.

It can deliver differentiated levels of energy with shortened procedure times, and also incorporates built-in digital cameras with LED lights and sensing electrodes on the balloon to allow for real-time visualisation and assessment of catheter electrode contact.

This device has shown promise in clinical trials and is expected to receive European CE Mark approval in late 2018.

Joe Fitzgerald, president of rhythm management at Boston Scientific, said: "The acquisition of Apama further advances our continued investment in the electrophysiology category, and, upon commercialisation, would broaden our portfolio of differentiated arrhythmia solutions."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.